The National Breast Cancer Foundation (NBCF) is Australia’s leading national body funding game-changing breast cancer research with money raised entirely by the Australian public.
NBCF today announced Professor Sarah Hosking has advised of her intention to resign as CEO of NBCF, effective late November.
NBCF Chair, Professor Helen Zorbas AO, paid tribute to Professor Hosking following the announcement.
Professor Zorbas AO said, “Sarah joined NBCF in 2016 and under her leadership NBCF has enjoyed a period of tremendous growth and development”.
“During Professor Hosking’s time with NBCF, she led the brand refresh and successfully enabled the new collaborative joint venture company with three other charities, new schemes that saw the appointment of three 10-year professors in an initiative that was the first of its kind in Australia.”
“Professor Hosking also oversaw the successful linkage grants with other single site cancers that have created greater opportunity for learnings between cancers both in research and future management.”
Professor Hosking said “This has been a very difficult decision and I celebrate the NBCF team who have been outstanding to work with every day, even through the COVID 19 pandemic which we weathered with courage, pride and ingenuity. None of these things happened easily or overnight, requiring a willingness to try new things and I thank the NBCF Board for their ongoing support.
“I have been incredibly proud to lead this organisation for the past 6 years, knowing that it makes such a profound contribution to the lives of Australians with breast cancer however the time has come for me to consider the next chapter for me and my family.”
“NBCF is poised perfectly for the next phase of its evolution and while I leave knowing that our capable team will make great things happen, we continue to need your support so that our important mission to stop deaths from breast cancer will be achieved.”
The NBCF Board will complete a full recruitment process to ensure a smooth leadership transition in this exciting time of breast cancer research.